Click here for more information about Algenuity
Click here for more information about LiqofluxPhenometrics Buy 3 Get 1 Free
Visit cricatalyst.com!Evodos Separation Technology Check out more of The Buzz spacer

Lumen Bioscience patents spirulina genetic engineering

November 27, 2018
AlgaeIndustryMagazine.com

Lumen Bioscience, a Seattle biotechnology company focused on orally delivered antibody therapeutics and other biologics, has announced that the U.S. Patent and Trademark Office has issued the company Patent No. 10,131,870, entitled “Targeted Mutagenesis in Spirulina.”

Like many single-cell organisms spirulina reproduces asexually, which means that it is not possible to improve it by using traditional plant breeding approaches. Despite intense effort, and widespread recognition of its potential importance, spirulina has resisted all attempts, according to the company, to enhance its biology using biotechnology tools that are widely used in drug development for other biological systems such as yeast and CHO. As a consequence, Lumen representatives say, essentially no work has been done to improve the productivity or nutritional profile of this inexpensive, vitamin-rich protein source, nor has the opportunity to use spirulina for synthesis of high-value products been realized.

With the issuance of this patent, Lumen’s researchers now announce that they have developed a novel set of bioengineering tools and methods that finally allow researchers to introduce targeted, highly stable genetic modifications into spirulina. This development, the researchers say, opens the door to converting this global foodstock into a platform for producing a wide range of novel chemical and biologic products, especially medical therapeutics and vaccines.

With Lumen’s technology, researchers can now edit or remove existing spirulina genes, or insert completely new genes directly into any desired location in the spirulina chromosome, and see those changes persist indefinitely. Lumen itself is using this new technology to develop high-value proteins and other molecules for foods, cosmetics, medicine, and industry.

“The history of the biotechnology industry can be written as the story of new platform organisms – from E. coli to yeast to mammalian cells – that suddenly enable products that were previously impractical or impossible. Our discovery of spirulina genetic engineering is the next chapter in that book,” said Jim Roberts, MD PhD, Lumen’s CSO and a co-inventor on the patent. “Our goal is to make this breakthrough technology as widely available as possible, through interactions, licenses and collaborations with companies and academic researchers worldwide.”

For drug development, this means faster timelines, higher chances of clinical success, and lower costs compared to traditional production systems. While tremendously successful for many applications, these older workhorses of the biotechnology industry have proven unsuitable for the large-scale production of certain classes of proteins and other biologics. Moreover, the cost of producing therapeutics in spirulina is 100-fold less expensive than previously possible using the older biotechnology platforms.

The new spirulina platform is also a significant advance over plant-based biotechnology platforms that have been evaluated in the past, that have failed to gain commercial traction despite showing initial promise. Spirulina can make 100 times more active therapeutic protein than food crop or tobacco plant-based expression systems and the resulting drugs can be administered without expensive processing and purification. This, according to the company, makes the Lumen Spirulina platform an ideal system company for making orally delivered biologics such as antibody therapeutics, a long-felt unmet need in healthcare.

The potential of Lumen’s technology has already led to collaborative efforts with groups including the Bill & Melinda Gates Foundation, the National Institutes of Health, and several leading U.S. research universities, to address such critical targets as ultra-low-cost antibody therapeutics for children in developing countries, oral vaccines against infectious viruses, and other new biologics.

To date, Lumen has been granted 20 composition of matter and pathway patents, and 41 new applications are currently pending, all of which relate to novel approaches to engineering spirulina and other cyanobacteria to create novel bio-based products. The new patent just announced also covers the proprietary strains used to produce Lumen’s first product, RioBlue™, which is a natural replacement for the petroleum-derived, artificial food color called “FD&C Blue #1.” Lumen produces RioBlue in its state-of-the-art cGMP production facility in Seattle, Washington. The broad composition-of-matter claims in the patent announced cover all engineered versions of this micro-organism, and therefore indirectly cover all of Lumen’s planned biologics products.

“This patent forms the cornerstone of Lumen’s comprehensive intellectual property strategy,” said Brian Finrow, Lumen’s CEO. “Aside from Columbia University’s patents in mammalian cell culture, and the University of Washington’s ‘Hall’ patents in yeast, it’s hard to think of another case where such broad protection was obtained for a novel platform biology. We look forward to working with our current collaborators and new potential licensees to explore the broad potential of this technology.”​

Information supplied by Lumen Bioscience

More Buzz…

Copyright ©2010-2019 AlgaeIndustryMagazine.com. All rights reserved. Permission required to reprint this article in its entirety. Must include copyright statement and live hyperlinks. Contact editorial@algaeindustrymagazine.com. A.I.M. accepts unsolicited manuscripts for consideration, and takes no responsibility for the validity of claims made in submitted editorial.

twittertopbarlinks_eventstopbarlinks_requesttopbarlinks_archives

From The A.I.M. Archives

— Refresh Page for More Choices
The Utah Science Technology and Research (USTAR) initiative, a technology-based economic development program funded by the state of Utah, has awarded a $175,320 grant for...
JapanNews.com reports that Euglena Co., a Tokyo-based maker of nutritional supplements, is spending ¥5.8 billion ($5.3 million USD) on building a test refinery that conve...
Hayley Dunning writes from the Imperial College of London that a new discovery has changed our understanding of the basic mechanism of photosynthesis and should rewrite t...
Amy Thompson writes in Space.com that SpaceX successfully launched its 15th Space Station cargo-resupply mission on Friday, June 29; carrying a payload of experiments des...
San Diego, CA and Kailua-Kona, HI-based Cellana, Inc. has signed an Asset Purchase Agreement with Cyanotech Corporation for the sale of Cellana’s six-acre production and ...
Cécile Barbière writes for Euractive.fr (translated by Rob Kirby) that, in large greenhouses formerly home to the tomatoes and cucumbers of the market gardening Groupe Ol...
Nature.com reports that swimming algae have been enlisted to carry drugs to individual cells, raising the prospect that such “microswimmers” could deliver targeted therap...
Julianna Photopoulos writes in Horizon EU Research and Innovation magazine that UK start-up Skipping Rocks Lab aims to use natural materials extracted from plants and sea...
Jason Huffman writes in UndercurrentNews.com that the Kampachi Company, a mariculture business focused on expanding the environmentally sound production of sashimi-grade ...
Steve Fountain writes in fortstocktonpioneer.com that, amid the 800-page law that last month set the country’s farm policy through 2023, is the expansion of federal suppo...
Jessica D'Lima writes in AdvancedScienceNews.com that medicine is moving towards minimally invasive procedures, which have important patient-oriented benefits such as sho...
Susan Kraemer writes in solarpaces.org that to use solar thermal energy to convert farmed algae to fuel, the solar fuels research team at Australian National University (...